Ipsen Acquires Kartos Therapeutics for Up to $1.75B

Summary Ipsen agreed to acquire Kartos Therapeutics for $450 million upfront plus up to $1.3 billion in regulatory and commercial milestones, creating a total potential transaction value of $1.75 billion. The acquisition gives Ipsen control of navtemadlin (KRT-232), an oral MDM2 inhibitor in Phase 3…